Pancreatic morbidity following minimally invasive radical gastrectomy

Minimally invasive gastrectomy has been now almost universally accepted as a valid option for the treatment of gastric cancer, with special reference to stage I malignancies (1-4). Actually, the well-known merits of minimally invasive surgery, such as reduced postoperative morbidity and shorter hospitalization with earlier return to daily activities are combined with the expected oncological outcomes.